Altana Omnaris nasal spray approval
This article was originally published in Pharmaceutical Approvals Monthly
Altana's Omnaris (ciclesonide nasal spray) for the treatment of allergic rhinitis in adults and children 12 years of age and older clears FDA Oct. 23. Altana said it hopes to secure a marketing partner before introducing the new molecular entity; the firm's current goal is a 2007 launch. Omnaris is simultaneously "approvable" for use in children ages 2-11. An inhalation formulation of ciclesonide, developed with Sanofi-Aventis under the trade name Alvesco, has been approvable for asthma since 2004 (1Pharmaceutical Approvals Monthly January 2006, p. 13)...
You may also be interested in...
Study design deficiences impeded Altana's attempt to distinguish Omnaris (ciclesonide) from other nasal corticosteroids as having less potential to suppress the cortisol system and adrenal function
Poorly executed pediatric trials impeded Altana’s attempt to gain approval of Omnaris (ciclesonide) nasal spray in children under 12 years old, FDA review documents indicate.
Bristol-Myers Squibb’s multi-targeted kinase inhibitor dasatinib and Genta’s Bcl-2 inhibitor Genasense (oblimersen) could be approved for leukemia indications in the first half of 2006, if granted priority reviews. Both agents were submitted in late December.